アルツハイマー病治療薬および診断薬：世界市場

世界のアルツハイマー病治療薬および診断薬の市場規模は、2023年の90億米ドル、2024年の97億米ドルから、予測期間中はCAGR 15.1％で推移し、2029年には196億米ドルに達すると予測されています。

ADバイオマーカー検査の部門は、2024年の58億米ドルから、予測期間中はCAGR 8.7%で推移し、2029年には88億米ドルに達すると予測されています。AD治療薬の部門は、2024年の39億米ドルから、CAGR 22.6%で推移し、2029年末には108億米ドルに達すると予測されています。

当レポートでは、世界のアルツハイマー病治療薬および診断薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場分析

第2章 市場概要

• アルツハイマー病の概要
• アルツハイマー病の病態生理学
• ADとアミロイドカスケード
• ADとタウオパチー
• ADと神経伝達物質システム
• ADの診断
• 認知状態テスト
• 脳画像
• 腰椎穿刺
• 血液バイオマーカー検査
• 遺伝子検査
• ADの薬物治療

第3章 市場力学

• 市場力学スナップショット
• 市場促進要因
• ADの発症率増加
• アンメットニーズの多さ
• 診断と医薬品開発におけるバイオマーカーへの注目の高まり
• 神経科学への公的および民間投資の増加
• 国民の意識の高まりと早期診断
• 後期臨床試験段階にある多数の薬剤
• 市場抑制要因
• 高コストの診断と新しい治療薬
• ブランド医薬品の特許切れとジェネリック医薬品の出現
• 医薬品開発における高い失敗率

第4章 新興技術と開発

• 新興技術/動向
• ADのスクリーニングと診断のための血液検査
• 疾患修飾小分子薬
• 転用医薬品
• AIと機械学習
• パイプライン分析
• 概要
• 治療目的タイプ
• フェーズ3開発中の新しいAD治療薬
• ターゲットタイプ別
• 病状別
• 開発中の新しいPET放射性トレーサー

第5章 市場セグメンテーション分析

• セグメンテーションの内訳
• 市場分析：検査タイプ別
• ADバイオマーカー検査市場：検査タイプ別
• AD治療薬市場：治療目的別
• AD治療薬市場：薬剤クラス別
• AD治療薬市場：薬剤タイプ別
• AD治療薬市場：病期別
• 地理的内訳
• 市場分析：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第6章 競合情報

• AD治療薬
• アルツハイマー病のジェネリック医薬品市場
• アルツハイマー病のブランド薬市場
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
• 併用薬（Memantine・Donepezil）
• AD診断薬
• 概要
• AD診断市場における製品の発売/承認

第7章 付録

• 調査手法
• 出典
• 略語
• 企業プロファイル
• ABBVIE INC.
• ALPHA COGNITION
• ALZPATH INC.
• AUROBINDO PHARMA
• BIOGEN
• C2N DIAGNOSTICS
• CORIUM LLC.
• DIADEM SRL
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• H.U. GROUP HOLDINGS INC.
• LABORATORY CORPORATION OF AMERICA HOLDINGS
• LILLY
• OTSUKA HOLDINGS CO. LTD.
• QUEST DIAGNOSTICS INC.

List of Tables

• Summary Table : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 1 : Brain Imaging Technologies and Application in the Alzheimer's Context
• Table 2 : Common Methods for AD Detection
• Table 3 : Key Clinical Biomarkers Used in the Diagnosis of AD
• Table 4 : NIH Funding Estimates for Alzheimer's Disease Research, 2017-2024
• Table 5 : Selected AD Biomarker-Focused Consortia
• Table 6 : Recent Therapeutic Programs Ceased Due to Failure in Clinical Trials
• Table 7 : Selected Blood Tests in Development for AD Screening/Diagnosis
• Table 8 : Disease Modifying Small Molecules AD Drug Candidates in Phase 3 Clinical Trials
• Table 9 : Disease Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
• Table 10 : Treatments for AD-Related Neuropsychiatric and Behavioral Symptoms in Phase 3 Clinical Trials
• Table 11 : Cognitive Enhancer AD Drug Candidates in Phase 3 Clinical Trials
• Table 12 : Radiopharmaceuticals for CNS Imaging in Clinical Development
• Table 13 : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 14 : Comparison of Biomarker Tests
• Table 15 : FDA-Approved PET Radiopharmaceuticals for AD Diagnosis
• Table 16 : CSF-Based IVD Tests for AD
• Table 17 : Blood Tests for AD Diagnosis
• Table 18 : Global Market for AD Biomarker Tests, by Test Type, Through 2029
• Table 19 : FDA-Approved Drugs to Treat Cognitive Symptoms of AD
• Table 20 : FDA-Approved Drugs to Treat Non-Cognitive Symptoms of AD
• Table 21 : Global Market for AD Therapeutics, by Therapeutic Purpose, Through 2029
• Table 22 : FDA-Approved AChEIs
• Table 23 : FDA-Approved Anti-Amyloid Antibodies
• Table 24 : Selected Anti-Inflammatory and Neuroprotective Agents in Phase 3 Clinical Trials
• Table 25 : Global Market for AD Therapeutics, by Drug Class, Through 2029
• Table 26 : Anti-Amyloid Drugs in Phase 3 Clinical Development
• Table 27 : Neurotransmitter Modulars in Clinical Trials Phase 3
• Table 28 : Global Market for AD Therapeutics, by Drug Type, Through 2029
• Table 29 : Patent Information for AD Drugs
• Table 30 : Number of Companies with Active FDA Approval to Market AD drugs in the U.S.
• Table 31 : FDA-Approved AD Drugs and Their Indications
• Table 32 : Global Market for AD Therapeutics, by Disease Stage, Through 2029
• Table 33 : Global Market for AD Therapeutics and Diagnostics, by Region, Through 2029
• Table 34 : North American Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 35 : North American Market for AD Therapeutics and Diagnostics, by Country, Through 2029
• Table 36 : U.S. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 37 : Canadian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 38 : Mexican Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 39 : European Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 40 : Europe Market for AD Therapeutics and Diagnostics, by Country, Through 2029
• Table 41 : German Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 42 : French Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 43 : U.K. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 44 : Italian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 45 : Rest of European Countries' Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 46 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 47 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Country, Through 2029
• Table 48 : Chinese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 49 : Japanese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 50 : Rest of Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 51 : RoW Market for AD Therapeutics and Diagnostics, by Type, Through 2029
• Table 52 : Key Companies in the U.S. Alzheimer's Generic Drug Market
• Table 53 : Commercially Available FDA-Approved Branded AD Drugs
• Table 54 : Companies with Active FDA Approval to Market Donepezil in the U.S.
• Table 55 : Companies with Active FDA Approval to Market Rivastigmine in the U.S.
• Table 56 : Companies with Active FDA Approval to Market Galantamine in U.S.
• Table 57 : Companies with Active FDA Approval to Market Memantine in the U.S.
• Table 58 : Companies with Active FDA Approval to Market Combination Therapy (Memantine and Donepezil) in the U.S.
• Table 59 : Selected Product Approvals/Launches in the AD Diagnostics Market, 2022-2024
• Table 60 : Information Sources in this Report
• Table 61 : Abbreviations Used in This Report
• Table 62 : AbbVie Inc.: Company Snapshot
• Table 63 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
• Table 64 : AbbVie Inc.: Product Portfolio
• Table 65 : AbbVie Inc.: News/Key Developments, 2024
• Table 66 : Alpha Cognition: Company Snapshot
• Table 67 : Alpha Cognition: Financial Performance, FY 2022 and 2023
• Table 68 : Alpha Cognition: Product Portfolio
• Table 69 : Alpha Cognition: News/Key Developments, 2024
• Table 70 : ALZpath Inc.: Company Snapshot
• Table 71 : ALZpath Inc.: Product Portfolio
• Table 72 : ALZpath Inc.: News/Key Developments, 2023 and 2024
• Table 73 : Aurobindo Pharma: Company Snapshot
• Table 74 : Aurobindo Pharma: Financial Performance, FY 2022 and 2023
• Table 75 : Aurobindo Pharma: Product Portfolio
• Table 76 : Aurobindo Pharma: News/Key Developments, 2023
• Table 77 : Biogen: Company Snapshot
• Table 78 : Biogen: Financial Performance, FY 2022 and 2023
• Table 79 : Biogen: Product Portfolio
• Table 80 : Biogen: News/Key Developments, 2023 and 2024
• Table 81 : C2N Diagnostics: Company Snapshot
• Table 82 : C2N Diagnostics: Product Portfolio
• Table 83 : C2N Diagnostics: News/Key Developments, 2023 and 2024
• Table 84 : Corium LLC.: Company Snapshot
• Table 85 : Corium LLC.: Product Portfolio
• Table 86 : Corium LLC.: News/Key Developments, 2022 and 2023
• Table 87 : Diadem srl: Company Snapshot
• Table 88 : Diadem srl: Product Portfolio
• Table 89 : Diadem srl: News/Key Developments, 2022 and 2023
• Table 90 : Eisai Co. Ltd.: Company Snapshot
• Table 91 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 92 : Eisai Co. Ltd.: Product Portfolio
• Table 93 : Eisai Co. Ltd.: News/Key Developments, 2022-2024
• Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
• Table 98 : H.U. Group Holdings Inc.: Company Snapshot
• Table 99 : H.U. Group Holdings Inc.: Financial Performance, FY 2022 and 2023
• Table 100 : H.U. Group Holdings Inc.: Product Portfolio
• Table 101 : H.U. Group Holdings Inc.: News/Key Developments, 2022-2024
• Table 102 : Laboratory Corporation of America Holdings: Company Snapshot
• Table 103 : Laboratory Corporation of America Holdings: Financial Performance, FY 2022 and 2023
• Table 104 : Laboratory Corporation of America Holdings: Product Portfolio
• Table 105 : Laboratory Corporation of America Holdings: News/Key Developments, 2022-2024
• Table 106 : Lilly: Company Snapshot
• Table 107 : Lilly: Financial Performance, FY 2022 and 2023
• Table 108 : Lilly: Product Portfolio
• Table 109 : Lilly: News/Key Developments, 2024
• Table 110 : Otsuka Holdings Co. Ltd.: Company Snapshot
• Table 111 : Otsuka Holdings Co. Ltd: Financial Performance, FY 2022 and 2023
• Table 112 : Otsuka Holdings Co. Ltd: Product Portfolio
• Table 113 : Otsuka Holdings Co. Ltd: News/Key Developments, 2023 and 2024
• Table 114 : Quest Diagnostics Inc.: Company Snapshot
• Table 115 : Quest Diagnostics Inc.: Financial Performance, FY 2022 and 2023
• Table 116 : Quest Diagnostics Inc.: Product Portfolio
• Table 117 : Quest Diagnostics Inc.: News/Key Developments, 2022-2024

List of Figures

• Summary Figure : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
• Figure 1 : Hypothetical Models for Progression of Alzheimer's Disease
• Figure 2 : Market Dynamics of Alzheimer's Disease Therapeutics and Diagnostics
• Figure 3 : Breakdown of Global Aging Population (65 or Older) with Alzheimer's-Associated Dementia, by Age Group, 2023
• Figure 4 : Breakdown of Dementia Cases in Japan, by Disease Type
• Figure 5 : Alzheimer's and Related Dementia Research Funding at the NIH, 2013-2023
• Figure 6 : Potential Use of Blood-Based Biomarkers in Primary Care
• Figure 7 : Novel Industry-Sponsored AD Therapeutic Agents in Clinical Development, by Clinical Trial Phase
• Figure 8 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Type
• Figure 9 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Subtype
• Figure 10 : Number of AD Clinical Trials for Most Common Targets, by Phase, as of Oct. 2024
• Figure 11 : Share of Active Clinical Trials for AD, by Disease State, as of Oct. 2024
• Figure 12 : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
• Figure 13 : Global Market Shares of AD Biomarker Tests, by Test Type, 2023
• Figure 14 : Global Market Shares of AD Therapeutics, by Therapeutic Purpose, 2023
• Figure 15 : Global Market Shares of AD Therapeutics, by Drug Class, 2023
• Figure 16 : Global Market Shares of AD Therapeutics, by Drug Type, 2023
• Figure 17 : Alzheimer's Disease (AD) Continuum
• Figure 18 : Global Market Shares of AD Therapeutics, by Disease Stage, 2023
• Figure 19 : Global Market for AD Therapeutics and Diagnostics, by Region, 2021-2029
• Figure 20 : Global Market Shares of AD Therapeutics and Diagnostics, by Region, 2023
• Figure 21 : North American Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
• Figure 22 : North American Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
• Figure 23 : European Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
• Figure 24 : European Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
• Figure 25 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
• Figure 26 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
• Figure 27 : RoW Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
• Figure 28 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 29 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 30 : Aurobindo Pharma: Revenue Share, by Business Unit, FY 2023
• Figure 31 : Aurobindo Pharma: Revenue Share, by Country/Region, FY 2023
• Figure 32 : Biogen: Revenue Share, by Business Unit, FY 2023
• Figure 33 : Biogen: Revenue Share, by Country/Region, FY 2023
• Figure 34 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 35 : Eisai Co. Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 36 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 37 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 38 : Laboratory Corporation of America Holdings: Revenue Share, by Business Unit, FY 2023
• Figure 39 : Lilly: Revenue Share, by Business Unit, FY 2023
• Figure 40 : Lilly: Revenue Share, by Country/Region, FY 2023
• Figure 41 : Otsuka Holdings Co. Ltd: Revenue Share, by Business Unit, FY 2023
• Figure 42 : Otsuka Holdings Co. Ltd: Revenue Share, by Country/Region, FY 2023
• Figure 43 : Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2023

The global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029, at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2029.

The global market for AD biomarker tests is expected to grow from $5.8 billion in 2024 to $8.8 billion by 2029, at a CAGR of 8.7% from 2024 to 2029.

The global market for AD therapeutics is expected to grow from $3.9 billion in 2024 to $10.8 billion by 2029, at a CAGR of 22.6% from 2024 to 2029.

Report Scope

This report focuses on the global market for Alzheimer's disease (AD) diagnostics and therapeutics, offering an updated review of this rapidly emerging market. In this report, the diagnostic market covers only biomarker tests for AD. Cognitive tests and neuroimaging diagnostic methods assessing structural changes are not part of the market calculations. The diagnostics market segmentation is based on the test type and region.

The therapeutics segment covers pharmacological treatments (drugs) only. This report does not cover alternative treatment options, such as procedural interventions. Additionally, many medications are used "off-label" to manage non-cognitive symptoms, such as agitation and depression, associated with dementia due to AD. This report does not cover off-label drugs used in the treatment of Alzheimer's. The therapeutics market segmentation is based on purpose, drug class, drug type, disease stage, and region.

An analysis of clinical trials, innovations, opportunities, and the latest trends in the AD diagnostics and therapeutics market are also discussed in the report.

Report Includes

• 38 data tables and 80 additional tables
• Analyses of the trends in the global market for Alzheimer's disease (AD) therapeutics and diagnostics, with market revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecasts for 2024-2025, and projected CAGRs through 2029
• Estimates of the size of the global market and revenue growth prospects, along with a market share analysis by type, therapeutic application, drug classification, mechanism of action, disease state of indication and region
• Facts and figures pertaining to key market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Identification of diagnostic tools and equipment; scientific and technological frameworks; drug profiles, clinical groundworks; and coverage of global developments
• Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease, as well as the promising new drug candidates and diagnostic imaging agents
• An analysis of patents, emerging trends and the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Profiles of leading companies, including AbbVie Inc., Biogen, Eisai Co. Ltd., Eli Lilly and Co., and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Alzheimer's Disease Overview
• Alzheimer's Disease Pathophysiology
• AD and Amyloid Cascade
• AD and Tauopathy
• AD and Neurotransmitter Systems
• Diagnosis of AD
• Cognitive Status Testing
• Brain Imaging
• Lumbar Puncture
• Blood-Biomarker Tests
• Genetic Testing
• Pharmaceutical Treatment of AD

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Growing Incidence of AD
• High Unmet Need
• Growing Focus on Biomarkers in Diagnosis and Drug Development
• Increasing Public and Private investment in Neuroscience
• Growing Public Awareness and Early Diagnosis
• Large Number of Drugs in Late-Stage Clinical Trials
• Market Restraints
• High Costs of Diagnostics and Novel Therapies
• Patent Expirations of Branded Drugs and Emergence of Generics
• High Failure Rate in Drug Development

Chapter 4 Emerging Technologies and Developments

• Emerging Technologies/Trends
• Blood Tests for AD Screening and Diagnosis
• Disease Modifying Small-Molecule Drugs
• Re-purposed Drugs
• AI and Machine Learning
• Pipeline Analysis
• Overview
• Therapeutic Purpose Type
• Novel AD Therapeutics in Development in Phase 3
• By Target Type
• By Disease State
• Novel PET Radiotracers in Development

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis, by Test Type
• AD Biomarker Tests Market, by Test Type
• AD Therapeutics Market, by Therapeutic Purpose
• AD Therapeutics Market, by Drug Class
• AD Therapeutics Market, by Drug Type
• AD Therapeutics Market, by Disease Stage
• Geographic Breakdown
• Market Analysis, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 6 Competitive Intelligence

• AD Therapeutics
• Alzheimer's Generic Drug Market
• Alzheimer's Branded Drug Market
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
• Combination Therapy (Memantine and Donepezil)
• AD Diagnostics
• Overview
• Product Launches/Approvals in the AD Diagnostics Market

Chapter 7 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ALPHA COGNITION
• ALZPATH INC.
• AUROBINDO PHARMA
• BIOGEN
• C2N DIAGNOSTICS
• CORIUM LLC.
• DIADEM SRL
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• H.U. GROUP HOLDINGS INC.
• LABORATORY CORPORATION OF AMERICA HOLDINGS
• LILLY
• OTSUKA HOLDINGS CO. LTD.
• QUEST DIAGNOSTICS INC.